Linden Thomas Advisory Services LLC Buys 105 Shares of ResMed Inc. (NYSE:RMD)

Linden Thomas Advisory Services LLC boosted its position in ResMed Inc. (NYSE:RMD) by 1.6% during the fourth quarter, Holdings Channel reports. The fund owned 6,490 shares of the medical equipment provider’s stock after acquiring an additional 105 shares during the period. Linden Thomas Advisory Services LLC’s holdings in ResMed were worth $1,116,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. CWM LLC increased its position in shares of ResMed by 44.8% during the 3rd quarter. CWM LLC now owns 3,881 shares of the medical equipment provider’s stock valued at $574,000 after purchasing an additional 1,200 shares during the last quarter. AE Wealth Management LLC boosted its stake in ResMed by 35.9% in the third quarter. AE Wealth Management LLC now owns 6,573 shares of the medical equipment provider’s stock worth $972,000 after buying an additional 1,738 shares in the last quarter. Global Retirement Partners LLC grew its position in ResMed by 12.9% during the third quarter. Global Retirement Partners LLC now owns 840 shares of the medical equipment provider’s stock valued at $124,000 after acquiring an additional 96 shares during the last quarter. HB Wealth Management LLC purchased a new position in shares of ResMed during the third quarter worth approximately $223,000. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of ResMed in the 3rd quarter worth approximately $134,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In other news, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other ResMed news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the completion of the sale, the general counsel now directly owns 6,688 shares in the company, valued at approximately $1,158,696. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the completion of the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,216 shares of company stock worth $2,046,617. 1.21% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on RMD shares. UBS Group increased their target price on shares of ResMed from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Oppenheimer raised their price objective on ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Mizuho reissued a “buy” rating and issued a $215.00 target price on shares of ResMed in a research note on Wednesday, March 27th. KeyCorp started coverage on ResMed in a report on Tuesday, February 6th. They set an “overweight” rating and a $227.00 target price for the company. Finally, Royal Bank of Canada lifted their price target on ResMed from $181.00 to $182.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 25th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, ResMed presently has an average rating of “Moderate Buy” and an average price target of $199.20.

ResMed Trading Down 0.3 %

NYSE RMD opened at $183.74 on Thursday. The stock has a market cap of $27.03 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 2.26 and a beta of 0.67. ResMed Inc. has a fifty-two week low of $132.24 and a fifty-two week high of $243.52. The stock has a 50 day simple moving average of $186.30 and a two-hundred day simple moving average of $171.39. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.15 billion. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm’s revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.66 earnings per share. On average, analysts forecast that ResMed Inc. will post 7.47 earnings per share for the current year.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.